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The American Heart Association predicted the rise in the prevalence 
of cardiovascular disease as 38.7% by 2020, where the coronary heart 
disease would rise for 8.6% and stroke for 3.6%.[1] In South Africa (SA), 
Liberty Life Insurance group has forecast the premature deaths due to 
heart and blood vessel diseases in people of working age (35 - 64 years) 
to increase by 41% between 2007 and 2030, with a warning of enormous 
negative economic impact.[2] Locally, an increased awareness of 
cardiovascular disease at the Dr George Mukhari referral hospital has led 
to more requests for plasma lipid profiles comprising fasting triglyceride 
(TG), total cholesterol (TC), high-density lipoprotein (HDL) cholesterol 
(HDLC) and low-density lipoprotein (LDL) cholesterol (LDLC). In 2013, 
18 234 lipid profiles from 7 255 patients were analysed compared with 
24 656 requests for 6 348 patients in 2014. The 35% increase occurred 
despite opening a new antiretroviral (ARV) clinic in the neighbourhood, 
which reduced patient flow at the tertiary hospital, and the introduction 
of electronic gatekeeping. Requests were in response to patients’ 
history of early death among first-degree relatives due to heart disease 
and stroke,[3] and cardiovascular risk suggested by obesity, metabolic 
syndrome, smoking, sedentary lifestyle, lack of exercise and stressful 
living. Genetic disorders in lipoprotein metabolic pathways generally 
have a greater impact on risk and typically display more severe and/
or persistent lipid abnormalities after treating the secondary factors. [4,5] 
Cascade testing of the family is advised.[6] Admixture of primary and 
secondary causes is especially evident in Fredrickson hyperlipidaemia 
types III, IV and V, where predisposing variant genes are stressed by diet, 
obesity with insulin resistance, hormonal derangements and alcohol 
intake. In SA, at least three low-density lipoprotein receptor (LDLR) 
mutations are known in Afrikaans-speaking whites, one in Jewish people 
from Eastern Europe and one in Indians of Gujerati descent.[7,8] Familial 
hypercholesterolaemia (FH) is mostly due to a pathogenic mutation 
in one of three genes (LDLR, apolipoprotein B (apoB) or proprotein 
convertase subtilisin/kexin type 9). FH is relatively common (prevalence 
1:200 - 1:500) and is therefore the most important monogenic disorder 
of lipoprotein metabolism. It exists as either heterozygous, where only 
one allele of the gene involved is mutated and the other allele is normal, 
or homozygous, where both alleles are abnormal. Persons with untreated 
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Background. The prevalence of cardiovascular disease is projected to be 38.7% for the USA in 2020, including coronary heart disease at 8.6% 
and stroke at 3.6%. In South Africa (SA), premature deaths due to heart and blood vessel diseases in people of working age (35 - 64 years) have 
been predicted to increase by 41% between 2007 and 2030, with enormous negative economic impact. Atherosclerosis underlies much of the 
pathogenesis, which involves risk factors including dyslipidaemia. Secondary dyslipidaemia associated with diabetes mellitus, hypothyroidism, 
chronic renal disease, cholestasis, nephrotic syndrome, alcohol excess, drugs such as thiazide diuretics and antiretroviral agents may respond 
to treatment of underlying causes, but residual dyslipidaemia may in such cases be due to primary disorders of metabolism. Primary 
dyslipidaemias are uncommon and to a large extent underdiagnosed, especially in the black population of SA, reflecting a lack of clinical and 
laboratory awareness or expertise. Specific diagnoses enable effective intervention in the patients as well as the families.
Objective. To assess the burden and prevalence of dyslipidaemia in the SA black population at Dr George Mukhari Hospital in the north 
region of Gauteng.
Method. A retrospective data analysis of 12-month lipid profiles comprising triglyceride (TG), total cholesterol (TC), high-density 
lipoprotein cholesterol and directly measured low-density lipoprotein (LDL) cholesterol (LDLC). 
Results. There were 24 656 requests for 6 348 patients. The lipid cut-off levels were somewhat arbitrary but were based on the commonly used 
decision-making levels in the treatment guidelines. Severe hypercholesterolaemia (>7 mmol/L) was seen in 299 (4.7%) patients and extreme 
hypercholesterolaemia (>12 mmol/L) was seen in 30 (0.5%) patients. LDLC (>5 mmol/L) occurred in 80 (1.3%) patients and >10 mmol/L 
in 19 (0.3%) patients. A predominant triglyceride problem was seen in 578 (9.1%) patients with TG (>2 mmol/L) and TC (<5 mmol/L), 
whereas moderate hypertriglyceridaemia (>5 mmol/L) was present in 113 (1.8%) patients, and more severe hypertriglyceridaemia
(>10 mmol/L) in 10 (0.2%). TC (>5 mmol/L) with LDL (>3 mmol/L) but TG in the normal range was seen in 369 (5.8%) patients, indicating 
a cholesterol-predominant problem. In contrast, LDLC (>3 mmol/L) and TG (>1.7 mmol/L) was seen in 249 (3.87%) representing mixed 
hyperlipidaemia. Paediatric patients with severe dyslipidaemia mostly suffered from nephrotic syndrome.
Conclusion. A significant burden and a high prevalence of dyslipidaemias were present in adults in whom a monogenic disorder should 
be considered. The extent and severity of dyslipidaemia justify a special clinic and laboratory to ensure accurate diagnosis with effective 
intervention for patients and their families.
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homozygous FH are at an approximately 
20-fold increased risk for coronary heart 
disease (CHD), which usually presents in their 
early 20s. Heterozygous FH is more common 
(no data for SA yet) and untreated men have 
a 50% risk of having a coronary event by 
age 50 years; untreated women are at a 30% 
risk by age 60 years.[9] FH has not been fully 
investigated in all SA population groups. 
The commonly held view that disorders of 
lipoprotein metabolism are absent in the SA 
black population needs to be dispelled, as it 
detracts from the recognition of disorders 
imparting high, but remediable, risk; especially 
if the previous (rural) lifestyle was protective 
against atherosclerosis as urbanisation 
increases cardiovascular diseases. A founder 
effect may exist in the black population for a 
six-nucleotide deletion.[9] The homozygous 
FH phenotype has been described in a 
patient with LDLR mutations and auto-
somal recessive hypercholesterola emia.[10] 
Dysbetalipoproteinaemia seems  com mon 
in black patients at an SA lipid clinic.[11] 
Other than apolipoprotein E (apoE2) allele 
2/2 homozygosity accounting for dysbeta-
lipoproteinaemia, De Villiers et al.[12] found 
that the apoE Arg145Cys mutation was present 
in patients of mixed ancestry, whites and more 
commonly in blacks in Cape Town. The mode 
of inheritance was autosomal dominant with 
delayed and incomplete penetrance.[12]
Most dyslipidaemias can be diagnosed by 
the lipid profile, but subtler dyslipidaemias 
in which triglyceride-rich particles such as 
very-low-density lipoprotein (VLDL) and 
intermediate-density lipoprotein accumu-
late, or the more atherogenic small dense 
LDL, are found to require more sophisti-
cated investigations. A non-denaturing 
gradient gel electrophoresis method was 
shown to be practical, cost-effective and 
a good diagnostic test for dysbeta lipo-
proteinaemia.[13,14]
The Dr George Mukhari Hospital is a 
tertiary referral hospital drawing patients 
from northern Gauteng, North West and 
Lim popo provinces. It is affiliated to Sefako 
Makgatho Health Sciences University 
(previ ously Medunsa). Most patients were 
indi genous black Africans. To study the 
prevalence of lipid abnormalities and 
recognition of monogenic disorders of 
lipoprotein metabolism in this population, 
an audit of the lipid requests was performed 
at this hospital.
Objectives
To assess the burden of lipid profile abnor-
malities and possible primary or familial 
dys lipidaemias at Dr George Mukhari 
Hospi tal, northern Gauteng, SA.
Methods
Analyses of plasma or serum were done in 
an accredited laboratory with commercially 
available enzymatic assays for TG and TC; 
homogenous immunoassay assays for HDLC 
and LDLC (direct) were performed with 
Synchron series reagent kits using a DXc 
automated analyser (Beckman Coulter, USA). 
The laboratory practised quality control to 
ensure that data were consistent and comparable 
with other laboratories. Samples were analysed 
in the fasted state, except in children.
A cross-sectional audit was done of 12 
months of data (1 January - 31 December 
2014) extracted from the laboratory infor-
mation system. Clinical files of patients with 
severe lipid abnormalities were viewed for 
clinical details and treatment and data were 
captured on Microsoft Excel (Microsoft 
Corporation, USA) without revealing identity. 
Adults mostly had only one test whereas in 
paediatric patients lipid profiles were often 
done 3-monthly. The numbers of patients 
with various dyslipidaemias were derived 
from the master database. Hypercholesterol-
aemia was taken as >5  mmol/L, severe as 
>7 mmol/L) and extreme as >12 mmol/L); the 
commensurate LDLC levels were 3 mmol/L, 
4 mmol/L, 5 mmol/L and 6 mmol/L taking a 
step wise approach of classifying the severity. 
Hyper triglyceridaemia was taken as mild 
(>2  mmol/L), moderate (>5 mmol/L) and 
severe (>10 mmol/L). These are convenient 
for clinical decision-making limits.
Patient identities were kept confidential. 
Relevant patients’ files were reviewed with 
the permission from the hospital manager.
Results
There were 24 656 lipid profiles for 6 348 
patients over 12 months. Table 1 summarises 
the mean, standard deviation (SD), median 
and range (minimum; maximum) for each 
lipid parameter extracted. The distribution 
of each component of the lipid profile is 
shown in Figs 1 - 4.
The data were analysed separately for 
adult and paediatric patients. In addition to 
the information on the request forms and 
patients’ files, locations (outpatient depart-
ments, clinics and wards) at the hospital 
from which the patient was referred also 
indicated chronic diseases, such as diabetes, 
HIV treated with ARVs, endocrine conditions 
such as hypothyroidism, and paediatric high 
care (nephrotic syndrome) and cardiac high 
care as well as cardiology outpatients. 
Table 2 summarises significantly deranged 
lipid levels and percentage of patients affected 
out of the total of 6 348 with clinical diagnoses 
indicated on the laboratory request forms. TC 
(<5 mmol/L) with TG (<1.7 mmol/L) (better 
lipid levels) was present in 3 574 (56.3%). The 
desired target of LDLC for primary prevention 
Table 1. Distribution of lipid parameters in the study population
  TC (mmol/L) LDLC (mmol/L) TG (mmol/L) HDLC (mmol/L)
Mean (SD) 4.42 (1.66) 2.32 (1.18) 1.50 (1.17) 1.13 (0.49)
Median 4.28 2.27 1.18 1.14
Minimum 0.38 0.07 0.10 0.13
Maximum 23.00 12.77 13.47 4.50
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Fig. 1. Total cholesterol distribution (results abridged).
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of atherosclerosis (>3  mmol/L) combined 
with a normal HDL (>2 mmol/L) was seen 
in 85 (1.2%) patients, indicating isolated 
LDL problem, while 99 (1.6%) patients had 
additional higher risk owing to low HDLC 
(<0.8 mmol/L) over and above their LDL 
being >3 mmol/L, indicating both LDL and 
HDL problems. Highlighting the cholesterol-
predominant problem, TC (>6 mmol/L) with 
LDL (>4 mmol/L) with TG in the normal 
range (<1.7 mmol/L) was seen in 176 
(2.8%) patients. To indicate a triglyceride-
predominant problem, TC (<5 mmol/L) with 
TG (>2.0 mmol/L) was seen in 602 (9.5%) 
patients. In another group, TC (>6.0 mmol/L), 
LDL (>4 mmol/L) and TG (>2.0 mmol/L) 
were seen in 322 (5.1%), representing mixed 
hyperlipidaemia and imposing cardio vascu lar 
risk.  Hyper cholesterol aemia from 5 mmol/L 
to 7  mmol/L was seen in 1 659 (26.1%) 
patients. Severe hypercholesterolaemia  was 
seen in 315 patients (5.0%) and extreme 
hyper cholesterol aemia was seen in 33 (0.5%) 
patients. These cases may indicate  under-
lying monogenic disorders as well as secon-
dary causes. While LDLC (>5 mmol/L) is 
frequently taken as a cut-point for FH, a 
stricter cut-off of >6 mmol/L was present 
in 78 (1.2%) patients and >8 mmol/L in 
19 (0.3%) patients. Hypertriglyceridaemia 
(>5  mmol/L) was present in 113 (1.8%) 
patients and >10 mmol/L in 10 (0.2%), 
signalling a risk for pancreatitis. HDLC 
(<0.8  mmol/L) was seen in 1  341 (21.1%) 
patients and hyperalphalipoproteinaemia 
(HDLC >2 mmol/L) was seen in 248 (3.9%) 
patients.
Table 3 provides the information on 
patients in whom secondary dyslipidaemia 
was excluded, as well as those on thiazides. 
The thiazides probably increase LDLC by 1 - 
2% and therefore any TC >7 mmol/L should 
still be counted as pathological.[15,16] Patients 
treated with simvastatin without initial lipid 
profiles in the laboratory information system 
had estimated levels by the calculation based 
on the LDLC lowering efficacy in African 
Americans. Adjusted LDLC = current LDLC 
+ 26% (±3%) for simvastatin 20 mg/day dose 
and + 21% (±1%) for simvastatin 10 mg once 
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Fig. 2. Triglyceride distribution (results abridged).
Table 2. Significantly deranged lipid levels and percentage of patients affected out of the total of 6 348 with clinical diagnoses (Dx) 
indicated on the laboratory request forms*
Lipid level 
(mmol/L) Patients, n (%)
TC >5 1 961 (30.9)
TC 5 - 7 1 659 (26.1)
TC >7 315 (5.0)
TC >12 33 (0.5)
TG >5 113 (1.8)
TG >10 10 (0.2)
LDLC >6 78 (1.2)
LDLC >8 19 (0.3)
HDLC <0.8 1 341 (21.1)
HDLC >2 254 (4.0)
Lipid level (mmol/L) Patients, n (%) Diabetes (%) CKD (%)
Liver 
Ds (%) Hypertension (%)
IHD/
CABG (%) NS (%) ARV (%)
No Dx 
indicated (%)
TC <5, TG <1.7 3 574 (56.3) Diagnosis not reviewed because these lipid levels are generally acceptable
TC >5, LDL >3, TG <1.7 777 (12.2) 30 5 0 30 10 10 10 5
TC >6, LDL >3, TG >2.0 322 (5.1) 45 10 1 30 10 4 0 0
TC <5, TG >2.0 602 (9.5) 20 20 0 5 0 15 5 35
LDLC >3, HDLC <0.8 99 (1.6) 25 12 3 20 20 20 0 0
LDLC >3, HDLC >2 85 (1.3) These patients overlapped with the group of TC >5 mmol/L, LDL >3 mmol/L and TG <1.7 mmol/L, so their 
diagnoses are not mentioned separately here
CKD = chronic kidney disease; Liver Ds = liver disease; IHD = ischaemic heart disease; CABG = coronary artery bypass graft; NS = nephrotic syndrome.
*Information such as chronic alcoholism and drugs are not usually indicated on the request forms.
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a day (od) (taken from pravastatin 10 mg od dose from the reference 
cited, as there was no adjustment for simvastatin 10 mg od).[17] The 
ratio of TC/HDLC or LDLC/HDLC may be used to assess risk when 
dealing with moderate dyslipidaemia.[18] In addition, non-HDLC was 
also calculated as a guide to atherogenicity.[19]
A total of 555 requests came from 148 patients in the paediatric 
cohort (average 3 - 4 tests per patient in 12 months), almost all from 
inpatients. Table 4 presents the proportion of paediatric patients with 
lipid profiles significantly elevated. Eighteen out of 148 (12%) had TC 
>6 mmol/L and 49 (33.1%) patients had LDLC >3 mmol/L, while 10 
(7%) patients had LDLC >4 mmol/L and 31 (21%) patients had LDLC 
>5 mmol/L. Hypertriglyceridaemia of >1.7 mmol/L was present 
in 66  patients (44.6%), >2 mmol/L in 59 (40%) and >5 mmol/L in 
15 (10.1%). 
Clinical files of 46 paediatric patients (31 with LDLC >5 mmol/L 
and TG >5 mmol/L) were reviewed (Table 4). Of these, 23 (50%) 
were diabetic with glycated haemoglobin ranging from 7% to 10%, 
15 (32%) patients had nephrotic syndrome, of whom 5 had severe 
hypercholesterolaemia (7.5 - 14.4 mmol/L). Eight (17%) were HIV 
patients on protease inhibitor treatment. 
Discussion
This study revealed an awareness of dyslipi daemia and cardiovascular 
risk with co morbidities in adult and paediatric patients. While 
secondary causes were prominent in children, a large portion of 
adults had moderate dyslipidaemias associated with other risk factors 
such as hypertension and diabetes, and drugs such as thiazides could 
have contributed. Severe hyperlipidaemia suggestive of monogenic 
disorders of lipoprotein metabolism was likely to be present in a 
small proportion but was not specifically considered in the notes. 
Patients with abnormal lipid levels were not worked up using lipid 
electrophoresis on agarose gel or polyacrylamide gel in order to look 
for specific types of hyperlipidaemias. Moreover, additional tests such 
as lipoprotein (a), which poses independent risk for cardiovascular 
complications, were not evaluated. This has a negative impact on 
patient management as the significant hyperlipidaemias could, to 
some extent, be affected or underplayed by genetic mutations or 
polymorphisms. If these were detected by proper work-up, both 
patient and family could benefit.  
In the distribution graphs (Figs 1 - 4), the HDLC displayed a 
normal distribution, and TC and LDLC had some patients with 
strikingly low values that detracted from a normal distribution. 
Table 3. Demography and clinical profile with the lipid levels* in significantly affected (n=19) patients
Patient No. Age (yr) Gender Ethnicity TC LDLC 
Estimated initial 
LDLC, range TG HDLC 
Non-
HDLC  Diagnosis Medication
1 55 F SW 8.4 6.5 7.94 - 8.44 1.27 1.66 6.74 IHD Sim 20 mg
2 57 F S 8.6 7.0 8.59 - 9.08 1.63 1.36 7.24 CABG Sim 20 mg
3 61 M SW 6.3 4.7 6.93 - 7.36 1.22 1.55 4.75 AS Sim 20 mg + AHT
4 65 F SW 6.9 4.9 5.99 - 6.36 0.71 2.17 4.73 AMI Sim 20 mg
5 26 F V 6.6 4.8 No statins 1.12 1.73 4.87 CCF/PTB None
6 64 M S 7.4 5.9 8.7 - 9.24 1.54 1.23 6.17 AMI Sim 20 mg
7 59 F S 6.1 4.1 5.01 - 5.32 1.37 1.61 4.49 HLP Sim 20 mg
8 50 F P 7.1 5.6 6.84 - 7.27 1.31 1.20 5.90 AS & IHD Sim 20 mg
9 70 F P 9.6 7.3 No statins 1.29 1.45 8.15 IHD/HHF AHT
10 37 M S 6.2 4.6 5.62 - 5.97 0.87 1.28 4.92 AP Sim 20 mg
11 67 F SW 9.1 7.0 No statins 1.67 1.84 7.26 AP/HPT AHT
12 84 F SW 7.6 4.4 No statins 1.31 1.19 6.41 CCF/LVD Amiloride 5 mg
13 50 F SW 6.6 5.0 6.11 - 6.49 1.21 1.34 5.26 HLP Sim 20 mg 
14 21 M SW 6.8 5.4 No statins 0.66 1.52 5.28 PHT + smoking Digoxin
15 68 F SW 6.5 4.8 5.87 - 6.23 1.28 1.39 5.11 ACS Sim 20 mg 
16 50 F P 6.47 4.8 5.87 - 6.23 0.68 1.66 4.81 AMI Sim 20 mg
17 60 M P 6.16 5.66 No statins 0.96 1.23 4.93 CCF Amiloride, digoxin
18 51 F S 6.86 5.12 6.26 - 6.64 0.86 2.59 4.27 AP Sim 20 mg
19 55 F S 6.21 4.88 5.96 - 6.33 1.52 0.86 5.35 IHD Sim 20 mg
M = male; F = female; SW = Tswana; P = Pedi; V = Venda; S = Sotho; TS = Tsonga; Sim = simvastatin daily intake; AHT = antihypertensive therapy with no hydrochlorothiazide; ACS = acute 
coronary syndrome; AMI = acute myocardial infarction; AP = angina pectoris; HPT = hypertension; VHD = valvular heart disease; AS = aortic stenosis; BC = bradycardia; MS = mitral stenosis; 
CCF = congestive heart failure; PTB = pulmonary thrombo-embolism or tuberculosis; PHT = pulmonary hypertension; HLP = hyperlipidaemia; HHF = hypertensive heart failure.
*All lipid levels are reported in mmol/L. Non-HDL cholesterol >4 mmol/L is a risk factor for atherosclerotic cardiovascular disease.
Table 4. Numbers and percentages of paediatric patients 
affected, according to various lipid cut-off levels*
Patients Lipid level (mmol/L) n (%)
With high TC >6 18 (12.0)
With high LDL >3 49 (33.1)
>4 10 (7.0)
>5 31(21.0)
With high TG >1.7 66 (44.6)
>2 59 (40.0)
>5 15 (10.1)
*Diagnoses are described in the last paragraph of the ‘Results’ section.
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Thirty randomly selected patient files with 
TC <3 mmol/L and LDL <2 mmol/L were 
assessed and it was found that the bloods 
were taken for lipid levels during acute 
illness, such as acute myocardial infarction, 
which could represent apolipoproteins 
affected by negative acute phase reaction. 
Ten patients with lower levels of TC and 
TG (taken as a sample from TC <3 mmol/L 
and TG <1 mmol/L) were also found to 
have suffered from chronic cardiac failure 
with possible cardiac cirrhosis, which could 
have contributed to lower secretion of apoB 
100. Despite these, TG concentrations, not 
corrected for background glycerol, also 
showed the typical skewed distribution 
towards higher values that could be attri-
buted to patients with uncontrolled diabetes, 
chronic kidney disease and nephrotic syn-
drome. Upon closer examin ation of the 
combination of various lipid parameters 
at the relevant medical decision limits 
(Table  2), there was a large number of 
patients with TC >5 mmol/L, the level at 
which cholesterol-lowering therapy should 
have been initiated. Patients whose TC 
>7.0 mmol/L, which could be suggestive 
of underlying heterozygous FH, are at a 
much higher risk of coronary complications; 
this category justifies medication as well 
as lifestyle changes.[5] TC >5 mmol/L with 
LDL >3 mmol/L and TG <1.7 mmol/L 
was seen in 777 (12.2%), and this may 
represent polygenic hypercholesterolaemia, 
while TC >6 mmol/L, LDL >3 mmol/L 
and TG >2.0  mmol/L may reflect type 
IIb hyperlipidaemia as seen in 322 (5.1%) 
patients. TC <5 mmol/L with TG >2 mmol/L 
was seen in 602 (9.5%), and could indicate 
chronic disorders of lifestyle, including 
obesity, metabolic syndrome or medications. 
Not surprisingly, the patients with patterns 
of moderate dyslipidaemia had a relatively 
high prevalence of monogenic disorders. 
After evaluating the patient files, patients 
with severe dyslipidaemias diagnosed with 
ischaemic heart disease, hypertension and 
coronary heart disease were analysed. The 
adjusted initial LDLC levels of patients 
already on statins indicated possible under-
lying genetic disorders of LDL clearance. 
This subset of patients had no contributions 
to dyslipidaemias from secondary causes, 
and as mentioned before, patients with 
hypertension and on thiazide treatment are 
using a standard dose of 12.5 mg od, and 
at this level its effect on hyperlipidaemia 
is modest if not minimal.[18] The absence 
of causes of secondary dyslipidaemia in 
this severely hypercholesterolaemic group 
suggests either polygenic disorder, in which 
multiple polymorphisms of genes are 
involved in increased production of LDL, or 
reduced clearance of LDL due to underlying 
heterozygous FH.[10]
This study also revealed 637 (9.98%) 
patients who presented with cardiac isch-
aemia and coronary heart disease  – not 
shown in the tables, but obtained from 
the original data extract by filtering based 
on the hospital locations where such 
patients are exclusively cared for. In this 
population, striking dyslipidaemias without 
comorbidities were seen and may suggest 
primary dyslipidaemia, including FH. The 
ratio of TC/HDLC or LDLC/HDLC may 
be used to assess risk when dealing with 
moderate dyslipidaemia. [18] A ratio of TC/
HDLC >4 was seen in 2 475 patients, and a 
ratio of LDLC/HDLC >2 was seen in 2 912 
patients. Non-HDLC >4  mmol/L (indi-
cative of cardiovascular risk) was seen in 
1 567 patients.[19] A ratio of TC/TG >2.0 
was observed in 4 219 patients, and in the 
study of Blom et al.,[20] such a ratio was seen 
in patients with dysbetalipoproteinaemia, 
although the ratio can be highly variable. The 
Friede wald calculation permits derivation of 
LDLC when TG is <4.5 mmol/L, except in 
dysbetalipoproteinaemia. In 6  187 (97.5%) 
patients whose TG was <4.5 mmol/L (not 
shown in the tables), the calculated LDLC 
exceeded the directly measured LDLC by 
>1 mmol/L in 2 737 (43.11%) patients;  this 
may suggest dysbetalipoprotein aemia (type 
III hyperlipidaemia).[21] Severe hyper tri-
glyceridaemia compatible with Fredrick-
son type V was also noted, albeit in small 
numbers. 
Conclusion
These findings illustrate that various types 
of primary and secondary dyslipidaemias 
are seen in adult black patients at this 
hospital. Regarding paediatric patients, the 
majority presented with severe dyslipidaemia 
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Fig. 4. LDL distribution (results abridged).
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owing to underlying nephrotic syndrome, type I diabetes and ARV 
therapy, although unfavourable underlying genetic variations could 
not be excluded. The high prevalence of dyslipidaemias may herald 
cardiovascular disease in a population known to be undergoing lifestyle 
changes with urbanisation. Unlike the other comorbidities, hypertension 
does not affect the lipid profile per se but promotes atherosclerosis in a 
possible positive feedback loop. Unfavourable changes of TC, VLDLC, 
LDLC/HDLC and HDLC/TC during thiazide treatment, especially 
at the low dosage of 12.5 mg od may only be a small contributor, but 
to obtain a more favourable lipid profile, consideration may need to 
be given to lipid-neutral antihypertensive agents such as angiotensin-
converting enzyme inhibitors or calcium channel blockers.[18]
Ideally, further investigation should be undertaken to determine 
the cause(s) of the dyslipidaemias, by characterising the lipoprotein 
subsets (electrophoresis) and proceeding to appropriate genetic 
testing, to expedite cascade testing as well as to provide more accurate 
counselling about heritability. The information and interpretation of 
data in this study justify the establishment of a lipid clinic dedicated 
to work-up dyslipidaemias along with a laboratory that can perform 
more specialised tests. 
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